Bridging Science and Practice: A Comprehensive Approach to Fibrosing ILD Management
Released On
July 31, 2025
Expires On
July 31, 2026
Media Type
Internet
Completion Time
45 minutes
Specialty
Primary Care, Pulmonology, Rheumatology, Radiology
Topics
ILD, Pulmonary Fibrosis, Respiratory, Sclerosis/autoimmune/connective tissue disease
Providers/Grant Support
This activity is provided by Integrity CE, LLC.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credit Available
- Physicians - maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of community pulmonologists, rheumatologists, radiologists, primary care physicians, clinicians within the Care Center Network including specialist pulmonologists, and other physicians, as well as physician assistants, nurse practitioners, and other healthcare professionals who may be involved in managing care for patients with fibrosing interstitial lung disease (ILD).
Program Overview
Fibrosing ILD refers to a diverse group of chronic conditions characterized by progressive fibrosis in the lung interstitium, leading to declining lung function, worsening respiratory symptoms, diminished health-related quality of life, and early mortality. Despite progress in our understanding of its pathogenesis and the ongoing development of novel therapies, there remains no cure. Thus, timely intervention and personalized management by collaborative, multidisciplinary care teams remain crucial for optimizing clinical decision-making and achieving better patient outcomes.
We invite you to join this program, in which our esteemed faculty will discuss key strategies for early and accurate diagnosis, review current clinical trial evidence regarding new and emerging therapies, and provide expert guidance on tailoring treatment.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Discuss the inflammatory and fibrotic mechanisms that underlie the pathogenesis and progression of fibrosing ILD
- Utilize appropriate assessments, including comprehensive medical history, clinical examination, lung function evaluation, serologies, and high-resolution computed tomography, to effectively monitor progression of fibrosing ILD
- Create a treatment plan for reducing disease progression in patients with fibrosing ILD that is consistent with current expert recommendations
- Apply available clinical trial evidence to identify patients who are likely to benefit from emerging therapies if and when they become available
Faculty
Paul W. Noble, MD
Professor of Medicine
Director, Women’s Guild Lung Institute
Cedars-Sinai Medical Center
Los Angeles, California
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Paul W. Noble, MD does not have any financial relationships or relationships to products or devices with ineligible companies.
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2025 through July 31, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].